Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor–coregulator interactions

Oncogene volume 28, pages 575–586 (2009)Cite this article

Abstract

The breast cancer susceptibility gene 1 (BRCA1) is mutated in approximately 50% of hereditary breast cancers, and its expression is decreased in 30–40% of sporadic breast cancers, suggesting a general role in breast cancer development. BRCA1 physically and functionally interacts with estrogen receptor-α (ERα) and several transcriptional regulators. We investigated the relationship between cellular BRCA1 levels and tamoxifen sensitivity. Decreasing BRCA1 expression in breast cancer cells by small interfering RNA alleviated tamoxifen-mediated growth inhibition and abolished tamoxifen suppression of several endogenous ER-targeted genes. ER-stimulated transcription and cytoplasmic signaling was increased without detectable changes in ER or ER coregulator expression. Co-immunoprecipitation studies showed that with BRCA1 knockdown, tamoxifen-bound ERα was inappropriately associated with coactivators, and not effectively with corepressors. Chromatin immunoprecipitation studies demonstrated that with tamoxifen, BRCA1 knockdown did not change ERα promoter occupancy, but resulted in increased coactivator and decreased corepressor recruitment onto the endogenous cyclin D1 promoter. Our results suggest that decreased BRCA1 levels modify ERα-mediated transcription and regulation of cell proliferation in part by altering ERα–coregulator association. In the presence of tamoxifen, decreased BRCA1 expression results in increased coactivator and decreased corepressor recruitment on ER-regulated gene promoters.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Basu A, Rowan BG . (2005). Genes related to estrogen action in reproduction and breast cancer. Front Biosci 10: 2346–2372.

    Article  CAS  Google Scholar 

  • Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE . (2006). Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 8: R38.

    Article  PubMed Central  Google Scholar 

  • Bissonauth V, Shatenstein B, Ghadirian P . (2008). Nutrition and breast cancer among sporadic cases and gene mutation carriers: an overview. Cancer Detection and Prevention 32: 52–64.

    Article  Google Scholar 

  • Chen YM, Farmer AA, Chen CF, Jones DC, Chen PL, Lee WH . (1996). BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res 56: 3168–3172.

    CAS  PubMed  Google Scholar 

  • Clarke R, Liu MC, Bouker KB, Gu ZP, Lee RY, Zhu YL et al. (2003). Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22: 7316–7339.

    Article  CAS  PubMed Central  Google Scholar 

  • Clarke R, Skaar TC, Bouker KB, Davis N, Lee YR, Welch JN et al. (2001). Molecular and pharmacological aspects of antiestrogen resistance. J Steroid Biochem Mol Biol 76: 71–84.

    Article  CAS  Google Scholar 

  • Curtin D, Ferris HA, Hakli M, Gibson M, Janne OA, Palvimo JJ et al. (2004). Small nuclear RING finger protein stimulates the rat luteinizing hormone-beta promoter by interacting with Sp1 and steroidogenic factor-1 and protects from androgen suppression. Mol Endocrinol 18: 1263–1276.

    Article  CAS  Google Scholar 

  • de Mora JF, Brown M . (2000). AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20: 5041–5047.

    Article  CAS  Google Scholar 

  • Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL . (2003). Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 10: 179–186.

    Article  CAS  Google Scholar 

  • Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R et al. (2006). Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Annu Oncol 17: 818–826.

    Article  CAS  Google Scholar 

  • Dubik D, Shiu RPC . (1992). Mechanism of estrogen activation of C-Myc oncogene expression. Oncogene 7: 1587–1594.

    CAS  PubMed  Google Scholar 

  • Eakin CM, MacCoss MJ, Finney GL, Klevit RE . (2007). Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase. Proc Natl Acad Sci USA 104: 5794–5799.

    Article  CAS  Google Scholar 

  • Fan S, Wang JA, Yuan R, Ma Y, Meng Q, Erdos MR et al. (1999). BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284: 1354–1356.

    Article  CAS  Google Scholar 

  • Fan SJ, Ma YX, Wang CG, Yuan RQ, Meng QH, Wang JA et al. (2001). Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 20: 77–87.

    Article  CAS  Google Scholar 

  • Fan SJ, Ma YX, Wang CG, Yuan RQ, Meng QH, Wang JA et al. (2002). p300 modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res 62: 141–151.

    CAS  PubMed  Google Scholar 

  • Ferris HA, Walsh HE, Stevens J, Fallest PC, Shupnik MA . (2007). Luteinizing hormone beta promoter stimulation by adenylyl cyclase and cooperation with gonadotropin-releasing hormone 1 in transgenic mice and LBetaT2 cells. Biol Reprod 77: 1073–1080.

    Article  CAS  Google Scholar 

  • Fink M . (2006). Effects of chemotherapy and hormonal therapy for early breast cancer recurrence and 15-year survival. Strahlenther Onkol 182: 53–55.

    Google Scholar 

  • Fleming FJ, Hill ADK, McDermott EW, O'Higgins NJ, Young LS . (2004). Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. J Clin Endocrinol Metab 89: 375–383.

    Article  CAS  Google Scholar 

  • Fox EM, Bernaciak TM, Wen J, Weaver AM, Shupnik MA, Silva CM . (2008). Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Mol Endocrinol 22: 1781–1796.

    Article  CAS  PubMed Central  Google Scholar 

  • Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R et al. (2003). Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 9: 1259–1266.

    CAS  PubMed  Google Scholar 

  • Glover JNM, Williams RS, Lee MS . (2004). Interactions between BRCT repeats and phosphoproteins: tangled up in two. Trends in Biochemical Sciences 29: 579–585.

    Article  CAS  Google Scholar 

  • Graham JD, Roman SD, McGowan E, Sutherland RL, Clarke CL . (1995). Preferential stimulation of human progesterone receptor B expression by estrogen in T-47D human breast cancer cells. J Biol Chem 270: 30693–30700.

    Article  CAS  Google Scholar 

  • Hall JM, Couse JF, Korach KS . (2001). The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276: 36869–36872.

    Article  CAS  Google Scholar 

  • Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y et al. (2001). The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 276: 14537–14540.

    Article  CAS  Google Scholar 

  • Horner-Glister E, Maleki-Dizaji M, Guerin CJ, Johnson SM, Styles J, White INH . (2005). Influence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells. J Mol Endocrinol 35: 421–432.

    Article  CAS  Google Scholar 

  • Hu YF, Ghosh S, Amleh A, Yue W, Lu YZ, Katz A et al. (2005). Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene 24: 8343–8348.

    Article  CAS  Google Scholar 

  • Jones LP, Li ML, Halama ED, Ma YX, Lubet R, Grubbs CJ et al. (2005). Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer. Oncogene 24: 3554–3562.

    Article  CAS  Google Scholar 

  • Kenny FS, Hui R, Musgrove EA, Gee JMW, Blamey RW, Nicholson RI et al. (1999). Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 5: 2069–2076.

    CAS  PubMed  Google Scholar 

  • Kilker RL, Planas-Silva MD . (2006). Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells. Cancer Res 66: 11478–11484.

    Article  CAS  Google Scholar 

  • Krum SA, Miranda GA, Lin CW, Lane TF . (2003). BRCA1 associates with processive RNA polymerase II. J Biol Chem 278: 52012–52020.

    Article  CAS  Google Scholar 

  • Kurtev V, Margueron R, Kroboth K, Ogris E, Cavailles V, Seiser C . (2004). Transcriptional regulation by the repressor of estrogen receptor activity via recruitment of histone deacetylases. J Biol Chem 279: 24834–24843.

    Article  CAS  Google Scholar 

  • Lin VY, Resnick EM, Shupnik MA . (2003). Truncated estrogen receptor product-1 stimulates estrogen receptor alpha transcriptional activity by titration of repressor proteins. J Biol Chem 278: 38125–38131.

    Article  CAS  Google Scholar 

  • Liu XF, Bagchi MK . (2004). Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo. J Biol Chem 279: 15050–15058.

    Article  CAS  Google Scholar 

  • Ma YX, Hu CY, Riegel AT, Fan SJ, Rosen EM . (2007). Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity. Mol Endocrinol 21: 1905–1923.

    Article  CAS  Google Scholar 

  • Ma YX, Tomita Y, Fan SJ, Wu KM, Tong YZ, Zhao ZG et al. (2005). Structural determinants of the BRCA1: estrogen receptor interaction. Oncogene 24: 1831–1846.

    Article  CAS  Google Scholar 

  • Magdinier F, Ribieras S, Lenoir GM, Frappart L, Dante R . (1998). Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region. Oncogene 17: 3169–3176.

    Article  CAS  Google Scholar 

  • Murphy L, Cherlet T, Adeyinka A, Niu YL, Snell L, Watson P . (2004). Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo. Clin Cancer Res 10: 1354–1359.

    Article  CAS  PubMed Central  Google Scholar 

  • Murphy LC, Simon SLR, Parkes A, Leygue E, Dotzlaw H, Snell L et al. (2000). Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res 60: 6266–6271.

    CAS  PubMed  Google Scholar 

  • Narod SA, Foulkes WD . (2004). BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4: 665–676.

    Article  CAS  Google Scholar 

  • Petz LN, Ziegler YS, Schultz JR, Kim H, Kemper JK, Nardulli AM . (2004). Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites. J Steroid Biochem Mol Biol 88: 113–122.

    Article  CAS  PubMed Central  Google Scholar 

  • Razandi M, Pedram A, Rosen EM, Levin ER . (2004). BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Mol Cell Biol 24: 5900–5913.

    Article  CAS  PubMed Central  Google Scholar 

  • Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D et al. (2003). Cyclic, proteasome-mediated turnover of unliganded and liganded ER alpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11: 695–707.

    Article  CAS  Google Scholar 

  • Sabbah M, Courilleau D, Mester J, Redeuilh G . (1999). Estrogen induction of the cyclin D1 promoter: Involvement of a cAMP response-like element. Proc Natl Acad Sci USA 96: 11217–11222.

    Article  CAS  Google Scholar 

  • Schreihofer DA, Resnick EM, Lin VY, Shupnik MA . (2001). Ligand-independent activation of pituitary ER: dependence on PKA-stimulated pathways. Endocrinology 142: 3361–3368.

    Article  CAS  Google Scholar 

  • Shang YF, Brown M . (2002). Molecular determinants for the tissue specificity of SERMs. Science 295: 2465–2468.

    Article  CAS  Google Scholar 

  • Shang YF, Hu X, DiRenzo J, Lazar MA, Brown M . (2000). Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103: 843–852.

    Article  CAS  PubMed Central  Google Scholar 

  • Shupnik MA . (2004). Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 23: 7979–7989.

    Article  CAS  Google Scholar 

  • Smith CL, O'Malley BW . (2004). Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25: 45–71.

    Article  CAS  Google Scholar 

  • Srinivas G, Annab LA, Gopinath G, Banerji A, Srinivas P . (2004). Antisense blocking of BRCA1 enhances sensitivity to plumbagin but not tamoxifen in BG-1 ovarian cancer cells. Mol Carcinog 39: 15–25.

    Article  CAS  Google Scholar 

  • Starita LM, Horwitz AA, Keogh MC, Ishioka C, Parvin JD, Chiba N . (2005). BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II. J Biol Chem 280: 24498–24505.

    Article  CAS  Google Scholar 

  • Thasni KA, Rakesh S, Rojini G, Ratheeshkumar T, Srinivas G, Priya S . (2008). Estrogen-dependent cell signaling and apoptosis in BRCA1-blocked BG1 ovarian cancer cells in response to plumbagin and other chemotherapeutic agents. Annu Oncol 19: 696–705.

    Article  CAS  Google Scholar 

  • Tsai HW, Katzenellenbogen JA, Katzenellenbogen BS, Shupnik MA . (2004). Protein kinase A activation of estrogen receptor a transcription does not require proteasome activity and protects the receptor from ligand-mediated degradation. Endocrinology 145: 2730–2738.

    Article  CAS  Google Scholar 

  • Wu LJC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL et al. (1996). Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 14: 430–440.

    Article  CAS  Google Scholar 

  • Xu JW, Fan SJ, Rosen EM . (2005). Regulation of the estrogen-inducible gene expression profile by the breast cancer susceptibility gene BRCA1. Endocrinology 146: 2031–2047.

    Article  CAS  Google Scholar 

  • Yarden RI, Brody LC . (1999). BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci USA 96: 4983–4988.

    Article  CAS  Google Scholar 

  • Zheng L, Annab LA, Afshari CA, Lee WH, Boyer TG . (2001). BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci USA 98: 9587–9592.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Dr Sarah E Aiyar for technical advice and Dr Sarah Parsons for HER2 antibodies. The authors acknowledge support of the National Institutes of Health (DK57082 to MA Shupnik and CA93506 to R Li), the University of Virginia Cancer Center (P30-CA44579) and Women's Oncology Fund (MA Shupnik).

Author information

Authors and Affiliations

  1. Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA, USA

    J Wen & M A Shupnik

  2. Department of Molecular Medicine, Institute of Biotechnology, University of Texas, Health Science Center at San Antonio, San Antonio, TX, USA

    R Li & Y Lu

  3. Department of Medicine, School of Medicine, University of Virginia, Charlottesville, VA, USA

    M A Shupnik

Authors
  1. J Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M A Shupnik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M A Shupnik.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wen, J., Li, R., Lu, Y. et al. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor–coregulator interactions. Oncogene 28, 575–586 (2009). https://doi.org/10.1038/onc.2008.405

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2008.405

Keywords

This article is cited by

Search

Advanced search

Quick links